Abvc

ABVC BioPharma Inc

ABVC | $1.065 -2.29% 42K

(0.0% 1d) (-6.0% 1m) (68.2% 1y) (0.0% 2d) (0.0% 3d) (-4.4% 7d) (-2.49% volume)
Earnings Calendar: 2022-11-14
Market Cap: $ 11,246,848
https://abvcpharma.com
Sec Filling | Patents | 34 employees

ABVC BioPharma is a clinical-stage biopharmaceutical company focused on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process at world-famous research institutions (such as Stanford University, University of California at San Francisco, and Cedars-Sinai Medical Center). The company has an active pipeline of six drugs and one medical device (ABV-1701/Vitargus®) under development.

adhd

add to watch list Paper trade email alert is off

Press-releases

ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M
Published: 2024-04-10 (Crawled : 12:30) - globenewswire.com
ABVC | $1.065 -2.29% 42K

Wholesale Trade

| -10.66% | O: 5.74% H: 1.55% C: -11.63%
biopharma royalties global for

ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60M
Published: 2024-03-26 (Crawled : 12:30) - globenewswire.com
ABVC | $1.065 -2.29% 42K

Wholesale Trade

| 3.81% | O: 33.81% H: 3.2% C: -8.9%
vitargus biopharma royalties global deal

AiBtl BioPharma Inc. Completes $7.6M Land Deal: Exchanging Stock for Real Estate, Demonstrating the Value of ABVC's 23M AiBtl Share Ownership as Hundred Million Dollars
Published: 2024-03-21 (Crawled : 12:30) - globenewswire.com
ABVC | $1.065 -2.29% 42K

Wholesale Trade

| 0.93% | O: -0.54% H: 3.33% C: -1.32%
million biopharma

ABVC BioPharma, Inc. CEO Selected as 2024 Top 10 CEO in CEO Insights Asia Magazine
Published: 2024-03-19 (Crawled : 12:30) - globenewswire.com
ABVC | $1.065 -2.29% 42K

Wholesale Trade

| -6.03% | O: -1.72% H: 0.0% C: 0.0%
ceo asia

ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update
Published: 2024-03-14 (Crawled : 13:30) - globenewswire.com
ABVC | $1.065 -2.29% 42K

Wholesale Trade

| -11.38% | O: -0.81% H: 0.0% C: 0.0%
first business year update biopharma

ABVC's New Horizon for Oncology and Hematology Aims at Cancer Market of Several Hundred Billion Dollars
Published: 2024-02-27 (Crawled : 13:30) - globenewswire.com
ABVC | $1.065 -2.29% 42K

Wholesale Trade

| -10.66% | O: 0.82% H: 0.0% C: 0.0%
cancer market

ABVC BioPharma Executes a Definitive Agreement to Receive License Fees of $3M and Royalties of 2% on Future Revenues
Published: 2024-02-15 (Crawled : 13:30) - globenewswire.com
ABVC | $1.065 -2.29% 42K

Wholesale Trade

| -13.49% | O: -0.4% H: 0.0% C: 0.0%
license biopharma royalties agreement

ABVC BioPharma Receives Australian Patent, Valid Until 2040, for Its Treatment of Major Depressive Disorder (MDD)
Published: 2024-02-12 (Crawled : 13:30) - globenewswire.com
ABVC | $1.065 -2.29% 42K

Wholesale Trade

| -17.42% | O: -0.76% H: 3.05% C: 2.29%
treatment biopharma

ABVC Acquires $2.96 Million Worth of Land in Asia with Stocks Priced at $3.50 per Share
Published: 2024-02-08 (Crawled : 14:30) - globenewswire.com
ABVC | $1.065 -2.29% 42K

Wholesale Trade

| -22.14% | O: -0.71% H: 3.6% C: -6.47%
million asia

ABVC BioPharma and its Subsidiary Receive $460M From AiBtl BioPharma as the First Milestone Payment of Global Licensing Fees
Published: 2024-01-03 (Crawled : 12:30) - globenewswire.com
ABVC | $1.065 -2.29% 42K

Wholesale Trade

| -9.92% | O: 79.33% H: 12.91% C: -11.06%
first payment biopharma global milestone

See all

Last 15 days Sec forms

File Id

Form

Published Date

Transaction Date

Direction

Code

Amount Transacted

Owned Amount

ABVC BioPharma Inc

Press-releases

Last 15 days Sec forms

Your Today's Watch List

Gainers vs Losers

Top 10 Gainers

Last 48 Hours Insiders Buying

12 months watchlist earnings calendar